Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Generon (Shanghai) Says Neutropenia Candidate Meets Phase III Target

publication date: Jan 26, 2018

Generon (Shanghai) reported its recombinant biologic for chemotherapy-induced neutropenia met its primary efficacy endpoint in a China trial that enrolled patients with breast cancer. F-627 (Benegrastim/BineutaTM) is a second-gen human granulocyte colony-stimulating factor (rhG-CSF) dimer that Generon believes has best-in-class potential. The primary endpoint was the duration of grade 4 (severe) neutropenia in the first chemotherapy cycle. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China